SYRE
NASDAQ
$97.33
Spyre Therapeutics Inc (SYRE)
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company is headquartered in Waltham, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $103.93 (+6.78%)
Market Cap
$8.05B
Free Cash Flow Yield
-2.31%
Beta (5Y)
1.74
Price Chart
Valuation
Market Cap$8.05B
P/S650.22
P/B16.69
Profitability
Total Revenue (TTM)$502K
Gross Profit (TTM)-$172M
EBITDA-$234M
EPS-$2.47
Financial Health
Free Cash Flow Yield-2.31%
Growth & Risk
EPS 5Y CAGR-2.15%
FCF 5Y CAGR+18.74%
Beta (5Y)1.74
Sharpe Ratio2.81